Posted by Michael Wonder on 25 Mar 2021
FDA approves new indication for drug to treat neurogenic detrusor overactivity in paediatric patients
25 March 2021 - Today, the U.S. FDA approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity, a bladder dysfunction related to neurological impairment, in children ages three years and older.
Myrbetriq is also indicated for overactive bladder in adult patients.
